The heterogeneity of acute myeloid leukemia (AML) results from a complex network of
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …

Acute myeloid leukemia (AML) is a hematopoietic disorder in which there are too many
immature blood-forming cells accumulating in the bone marrow and interfering with the …

In recent years, research in genomics has resulted in the rapid uncovering of the molecular
pathogenesis of acute myeloid leukemia (AML). The identification of the genetic …

BACKGROUND AND OBJECTIVE: The successful use of differentiating treatment for
patients with acute promyelocytic leukemia (APL) suggests that other acute myeloid …

Acute myeloid leukemia (AML) is the most frequently diagnosed acute leukemia, and its
incidence increases with age. Although the etiology of AML remains unknown, exposure to …

Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …

Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by impaired
differentiation and uncontrollable proliferation of myeloid progenitor cells. Due to high …

The list of acquired mutations with clinical value in AML is growing. Clinical implementation
of this multitude of markers will require integrated approaches and selection of markers to …

In recent years, research in molecular genetics has been instrumental in deciphering the
molecular pathogenesis of acute myeloid leukemia (AML). With the advent of the novel …

Simple Summary Acute myeloid leukemia (AML) accounts for 7.6% of hematopoietic
malignancies with a long-term survival of less than 20%. Better understanding its …